Polpharma Biologics

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

News

NHS risks missing out on independent prescriber benefits

Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks